share_log

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

Benzinga ·  Dec 20, 2024 23:00  · Ratings

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $30 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment